A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus

Inclusion Criteria: * Male or female subjects aged 18-64 years (both inclusive) * Type 1 diabetes mellitus (as diagnosed clinically) ≥ 12 months * Treated with multiple daily insulin injections ≥ 12 months * Treated with an evening dose of once-daily insulin glargine U100 at screening * Fasting C-peptide ≤ 0.30 nmol/L Exclusion Criteria: * Known or suspected hypersensitivity to IMPs, paracetamol (acetaminophen) or related products * Type 2 diabetes mellitus * Clinically significant abnormal haematology, biochemistry, or urinalysis screening tests, as judged by the Investigator considering the underlying disease * Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea, vomiting, heartburn or diarrhoea), as judged by the Investigator * Known slowing of gastric emptying, including gastroparesis, and or gastrointestinal surgery that in the opinion of the investigator might change gastrointestinal motility and food absorption * Intake of medication known to affect gastrointestinal motility, including but not limited to erythromycin, metoclopramide, cisapride, cholestyramine or colestipol within 4 weeks before screening